Clinical Trial Detail

NCT ID NCT02451852
Title AZD9291 US Expanded Access Program
Recruitment No longer available
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: adult

No variant requirements are available.